DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report sent to investors on Thursday morning. The firm issued a hold rating on the stock.

A number of other research analysts have also issued reports on the stock. HC Wainwright raised their target price on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, October 24th. JMP Securities reiterated a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a research note on Tuesday, December 10th.

DBV Technologies Stock Performance

Shares of DBVT opened at $3.83 on Thursday. The firm has a market cap of $78.78 million, a PE ratio of -0.85 and a beta of 0.64. The firm’s 50 day moving average price is $3.29 and its 200 day moving average price is $3.82. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $9.50.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.